Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors (Q38550541)

4 September 2017

1 reference

title

Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors (English)

1 reference

4 September 2017

1 reference

3

Soldano Ferrone

1 reference

4 September 2017

Yangyang Wang

1

1 reference

4 September 2017

Claudia Geldres

series ordinal

2

1 reference

4 September 2017

Gianpietro Dotti

series ordinal

4

1 reference

4 September 2017

language of work or name

English

0 references

publication date

18 July 2015

1 reference

Expert Opinion on Therapeutic Targets

4 September 2017

published in

1 reference

4 September 2017

volume

19

1 reference

4 September 2017

issue

10

1 reference

4 September 2017

page(s)

1339-1350

1 reference

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Structure and function of extracellular matrix proteoglycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Sulfotransferases in glycosaminoglycan biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Recombinant production of proteoglycans and their bioactive domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Proteoglycan form and function: A comprehensive nomenclature of proteoglycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

The NG2 proteoglycan: past insights and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Uncoupling of chondroitin sulfate glycosaminoglycan synthesis by brefeldin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

A role for the NG2 proteoglycan in glioma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Early contribution of pericytes to angiogenic sprouting and tube formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

CSPG4 in cancer: multiple roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24(-)/CD65s( )/CD15( ) B-cell phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Human glioma-initiating cells show a distinct immature phenotype resembling but not identical to NG2 glia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Differential phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-863 in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Design and development of therapies using chimeric antigen receptor-expressing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

The promise and potential pitfalls of chimeric antigen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Transendothelial migration of lymphocytes mediated by intraendothelial vesicle stores rather than by extracellular chemokine depots.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

The integration of T cell migration, differentiation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4 T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Immunotherapy of human cancers using gene modified T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.2015.1068759

10.1517/14728222.2015.1068759

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference